Aurinia appoints founder Dr. Foster to board; enters cooperation agreement with MKT Capital

Aurinia Pharmaceuticals Inc.

Dr. Robert T. Foster appointed to Board effective Sept 21, 2023; term expires at 2024 Annual Meeting.
MKT Capital agrees to standstill until Oct 31, 2024 (with conditions) and 7% ownership cap.
Dr. Foster receives standard non-employee director compensation: $45K annual cash, $200K annual equity, $340K new director grant.
Dr. Foster retains 2% royalty on voclosporin licensee sales and 0.3% of direct net sales ($307,254 in FY2022).
Press release notes Dr. Foster discovered voclosporin; strategic review remains ongoing.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Robert T. Foster

Board member

AUPH · Aurinia Pharmaceuticals Inc.

Effective: 2023-09-21
Filed: September 21, 2023, 7:59 PM ET

In connection with the Cooperation Agreement, Dr. Foster was appointed to the Board, effective September 21, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Robert T. Foster was appointed as Board member at Aurinia Pharmaceuticals Inc..

Action: appointed
Role: Board member

Exact text from the filing

In connection with the Cooperation Agreement, Dr. Foster was appointed to the Board, effective September 21, 2023.

View on SEC.gov

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001600620-23-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.